Dutch health technology company Royal Philips (NYSE:PHG) (AEX:PHIA) on Wednesday introduced IntraSight Plus, an interventional cardiology platform cleared for clinical use in the United States and Europe, combining diagnostic and treatment planning tools into a single system.
The platform integrates multiple functions onto one interface, enabling clinicians to diagnose, plan, guide, and verify coronary procedures while supporting improved decision-making and patient outcomes.
Designed to address inefficiencies in percutaneous coronary interventions, where tools such as angiography, intravascular ultrasound, and physiology are often used separately, IntraSight Plus consolidates these capabilities into a unified workflow. The system is designed to reduce operational complexity in catheterisation labs and deliver up to 47% time savings during procedures.
The platform merges Philips' IntraSight and SyncVision technologies, incorporating IVUS and iFR/FFR physiology, alongside co-registration and real-time device visualisation. This integration enables enhanced procedural precision, streamlined data input and communication, and bedside control within the sterile field.
IntraSight Plus also connects with Philips' Azurion platform and PACS system, supporting broader integration within existing lab environments. The system is FDA 510(k) cleared and CE marked, with commercial availability subject to market release and regulatory requirements.
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
Abbott secures CE Mark for Cologuard Plus in Europe
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
SciBase technology selected as primary endpoint in NIH-led skin exposure study
FDA approves Vantis Vascular's 6F CrossFAST model
TWINBIRD launches portable freezer targeting dry-ice-free research cold chains
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay